

Factors associated with lack of improvement in submaximal exercise capacity of patients with heart failure

Tiny Jaarsma^{1*}, Naoko Perkiö Kato¹, Tuvia Ben Gal², Maria Bäck³, Oronzo Chialà⁴, Lorraine Evangelista⁵, Jan Mårtensson⁶, Massimo F. Piepoli^{7,8}, Ercole Vellone⁴, Leonie Klompstra¹, Anna Strömberg^{1,9} and HF-Wii study team

¹Department of Medicine, Health and Caring Sciences, Linköping University, Linköping, 58183, Sweden; ²Heart Failure Unit, Cardiology Department, Rabin Medical Center, Petah Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; ³Department of Medicine, Health and Caring Sciences, Division of Physiotherapy, Linköping University, Linköping, Sweden; ⁴Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; ⁵School of Nursing, The University of Texas Medical Branch, Galveston, TX, USA; ⁶Department of Nursing, School of Health and Welfare, Jönköping University, Jönköping, Sweden; ⁷Cardiology Unit, Guglielmo da Saliceto Hospital, AUSL, Piacenza, Italy; ⁸Fondazione Toscana "G Monasterio", Pisa, Italy; and ⁹Department of Cardiology, Linköping University, Linköping, Sweden

Abstract

Aims Improvement in exercise capacity is the primary goal of physical activity programmes for patients with heart failure (HF). Although activity programmes are effective for some patients, others do not benefit. Identifying factors related to a lack of improvement in submaximal exercise capacity may help us interpret findings and design new interventions. The aim of this study is to identify factors contributing to a lack of improvement in submaximal exercise capacity 3 months after physical activity advice or an exergame intervention in patients with HF. Additionally, we aimed to assess differences in lack of improvement in submaximal exercise capacity of patients whose baseline exercise capacity predicted a worse compared with better prognosis of HF.

Methods and results This secondary analysis of the HF-Wii study analysed baseline and 3 month data of the 6 min walk test (6MWT) from 480 patients (mean age 67 years, 72% male). Data were analysed separately in patients with a pre-defined 6 min walking distance at baseline of <300 m ($n = 79$) and ≥ 300 m ($n = 401$). Among patients with a baseline 6MWT of ≥ 300 m, 18% had deteriorated submaximal exercise capacity. In the multiple logistic regression analysis, lower baseline levels of self-reported physical activity [odds ratio (OR) = 0.77, 95% confidence interval (CI) = 0.60–0.97], lower baseline levels of cognitive function (OR = 0.87, 95%CI = 0.79–0.96) were significantly associated with lack of improvement in exercise capacity at 3 months. Not randomized to exergaming (OR = 0.63, 95%CI = 0.37–1.09) was likely ($P = 0.097$) to be associated with lack of improvement in exercise capacity at 3 months. Among the 79 patients with baseline 6MWT of <300 m, 41% ($n = 32$) did not improve 6MWT distance at 3 months. Independent predictors for the lack of improvement for 6MWT were New York Heart Association class III/IV (OR = 4.68, 95%CI = 1.08–20.35), higher levels of serum creatinine (OR = 1.02, 95%CI = 1.003–1.03), lower cognitive function (OR = 0.86, 95%CI = 0.75–0.99), and fewer anxiety symptoms (OR = 0.84, 95%CI = 0.72–0.98).

Conclusions Lower self-reported physical activity and cognitive impairment predict lack of improvement in submaximal exercise capacity in HF patients. Patients who have a worse prognosis (score <300 m at the 6MWT) are often frail and gain less in exercise capacity. These patients may need a more comprehensive approach to have an effect on exercise capacity, including an individually tailored exercise programme with aerobic exercise (if tolerated) and strength exercises.

Keywords Heart failure; 6 min walk test; Submaximal exercise capacity; Physical activity

Received: 7 May 2021; Revised: 22 June 2021; Accepted: 11 August 2021

*Correspondence to: Tiny Jaarsma, Department of Medicine, Health and Caring Sciences, Linköping University, 58183 Linköping, Sweden. Email: tiny.jaarsma@liu.se
The HF-Wii team: T. Jaarsma, A. Strömberg, L. Klompstra, J. Mårtensson, B. Ben Avraham, T. Ben Gal, J. Boyne, O. Chialà, L. Evangelista, A. Hagenow, E. Häggglund, and E. Vellone.

Introduction

Physical activity and exercise are essential for patients with heart failure (HF) to improve functional capacity, quality of life, and prognosis.^{1–3} It is recommended that patients with HF should be physically active daily and activities should be adapted to symptoms and personal preferences.⁴ However, several factors may hinder patients from being as physically active as they would wish to be, such as symptoms of breathlessness, fatigue, or lack of sport facilities.^{2,5} As HF is a progressive disease, it can be expected that a constant adaptation of physical activity is needed during the HF trajectory. If improvement cannot be realized, even maintaining a stable level of physical activity is valuable.

The 6 min walk test (6MWT) is a low-cost and reliable method for estimating submaximal exercise capacity; only a 30 m pre-measured level surface and a timing device are needed.⁶ The distance walked on the 6MWT is correlated with exercise duration and oxygen uptake at peak exercise and is used to assess interventions or determine subgroups of patients that might benefit from certain interventions.^{7–9} The 6MWT has been shown to have a strong predictive power for both mortality and morbidity in patients with HF.^{10–12} In a study of 1714 patients with HF, a decline in 6MWT was found to be associated with a worse prognosis and not modified by treatment up-titration.⁷ A threshold of 300 m at the 6MWT is associated with a worse (<300 m) and a better (\geq 300 m) prognosis in HF patients^{11,12} and a meaningful improvement in submaximal exercise capacity is previously defined as a change of more than 30 m.¹³ An increase of 30 to 50 m in 6MWT distance over time is previously considered a clinically significant improvement and found to be associated with a significant improvement in New York Heart Association functional class (NYHA) and health-related quality of life.^{14–16}

In the HF-Wii study,¹⁷ we tested the effect of an exergame intervention to improve physical activity in submaximal exercise capacity as measured by the 6MWT and compared it with a control group of patients whom only received physical activity advice. Although one-third of the patients improved submaximal exercise capacity during follow-up, many patients did not improve or even deteriorated in the 6MWT, both in the intervention and the control groups.

To understand further this lack of effect and to design optimally tailored physical activity interventions for the future, we aimed to identify factors related to lack of improvement and deterioration of submaximal exercise capacity 3 months after an exergame intervention or physical activity advice in patients with HF. Additionally, we aimed to assess differences in lack of improvement in submaximal exercise capacity of patients whose baseline exercise capacity predicted a worse (<300 m) vs. a better (\geq 300 m) prognosis.

Methods

Study design and participants

This study is a secondary data analysis from an international randomized controlled intervention study, the HF-Wii study, performed at 10 HF centres in Sweden, Italy, the Netherlands, Israel, Germany, and the United States, with recruitment between 2013 and 2017.^{17,18} Eligible participants (>18 years, no upper age limit) had been diagnosed with HF (NYHA class I–IV) independent of ejection fraction and spoke the language of the including country. Patients were excluded if they could not use the exergame due to visual, hearing, cognitive, or motor impairment, were unable to complete questionnaires or had a life expectancy < 6 months.

Patients were randomized to exergame (intervention) or physical activity advice (control). In the intervention group, the patients were instructed to exergame 30 min per 5 days a week, adapted to their physical condition. Patients were contacted by telephone after 2, 4, 8, and 12 weeks to discuss the frequency of playing or solve possible technical problems with the exergame platform. In the control group, patients received advice from medical staff in the HF team. They received telephone follow-up calls after 2, 4, 8, and 12 weeks to discuss their current physical activity.

The study was conducted according to the Declaration of Helsinki (2008) principles following the Medical Research Involving Human Subjects Act. In Sweden, ethical approval was obtained centrally (DNR 2012/247-31), and additional approval was obtained from the local medical ethics committees (the Netherlands NL48647.068.14/METC141085; Italy 0052838/272/U.V.F/1 (2014); Israel 0022-13-RMC; Germany S22(a)/2015; USA UCI IRB HS# 2016-2955). The trial is registered in ClinicalTrials.gov (NCT01785121).¹⁷

Measurements

Submaximal exercise capacity

To examine changes in submaximal exercise capacity at patient level, differences between the 6MWT at baseline and after 3 months were calculated per patient.¹⁰

According to the 2002 statement of the American Thoracic Society, the self-paced 6MWT assesses the submaximal level of functional capacity. Most patients do not achieve maximal exercise capacity during the 6MWT; instead, they choose their own intensity of exercise and are allowed to stop and rest during the test.¹⁹

As prior studies have shown that a threshold of 300 m at the 6MWT is associated with a worse (<300 m) and a better (\geq 300 m) prognosis in HF patients,¹¹ we divided patients into two groups: those who scored <300 m at the 6MWT at baseline and those who scored \geq 300 m. Moreover, considering that a meaningful improvement in submaximal exercise

capacity was defined as a change of >30 m from the baseline distance walked in the 6MWT,¹³ it is possible to formulate two assumptions:

- 1 if a patient has a relatively low baseline distance of 6MWT (<300 m), a positive outcome is a meaningful improvement of ≥ 30 m. A lack of improvement is defined as a difference of less than 30 m between baseline and follow-up.
- 2 if a patient had a relatively high baseline 6MWT distance (≥ 300 m), 6MWT distance should at least stay at the same level and not decline >30 m. So, for patients with a baseline 6MWT distance ≥ 300 m, a lack of improvement is defined as a decrease over time of more than 30 m.

Shortness of breath and fatigue were assessed with a numeric rating scale ranging from no experience of fatigue or shortness of breath (0) to worst experienced fatigue or shortness of breath (10).

Cognitive impairment was assessed with the Montreal Cognitive Assessment (MoCA), which is a brief screening instrument to detect mild cognitive impairment.²⁰ The MoCA scores range between 0 and 30. Higher MoCA scores indicate better cognitive function. A score of 26–30 is considered normal; 18–25 is considered a mild cognitive impairment, 10–17 is a moderate cognitive impairment, and less than 10 is considered a severe cognitive impairment.^{20,21}

Depression and anxiety were measured with the Hospital Anxiety and Depression Scale, consisting of 14 items (response scale 0–3), which are divided into two subscales of 7 items, each measuring anxiety and depression.²² Each scale has a score between 0 and 21, with a score ≥ 7 indicating the presence of depression and anxiety.²²

Exercise motivation was assessed by the Exercise Motivation Index, measuring exercise motivation using 15 statements on a 5-point scale from 0 (*not important*) to 4 (*extremely important*).²³

Self-efficacy was measured with the Exercise Self-Efficacy questionnaire, which measures the extent to which an individual feels confident to exercise despite six potential barriers. Possible scores range from 1 (*not very confident*) to 10 (*very confident*).²⁴

Self-reported physical activity was measured with a single-item question regarding the activity of the last week, with five answering options (1 = no activity, 2 = less than 30 min/week, 3 = 30–60 min/week, 4 = more than 1 to 3 h/week, 5 = more than 3 h a week).²⁵

The following *demographic and clinical variables* of patients were collected from the questionnaires and medical records: age, gender, marital status, education, NYHA classification, aetiology of HF, duration of HF, left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, pulse rate, blood pressure, serum haemoglobin, creatinine, body mass index, comorbidities, medications, and smoking status.

Statistical analysis

In all analyses, patients either from the intervention or the control groups were analysed as one group because we aimed to identify factors related to the lack of improvement in submaximal exercise capacity at 3 months, independent of allocated groups. However, in the analysis, we corrected for group assignment. Categorical data are presented as frequencies and percentages. For continuous variables with a normal distribution, the mean and standard deviations are reported. For variables not normally distributed, the median and interquartile ranges are reported. Student's *t*-test was used to compare normally distributed continuous data, and Mann–Whitney *U*-test was used for non-normally distributed continuous data. Categorical variables were compared with the χ^2 test or Fisher's exact test as appropriate.

To identify factors associated with a lack of improvement, three multiple logistic regression analyses were performed. Variables associated with a lack of improvement in univariate analysis ($P < 0.015$) were entered in the multivariate model and then selected using the backward selection method. Baseline 6MWT and group assignment were forcedly entered into the multivariate model.

Missing self-administered questionnaires were not replaced in the present analysis because there were only a few patients who had a few missing items in each instrument (approximately 0.006% to 0.04%) and, in most other cases, patients did not answer any items (0.01–0.02%).

All statistical tests were two-tailed, and statistical significance was defined as $P < 0.05$. All analyses were performed with SAS version 9.4 for Windows (SAS Institute Inc., Cary, North Carolina, USA).

Results

Of the 605 patients included in the HF-Wii study, 82 patients terminated the study prematurely, mostly due to medically related issues or refusal to continue, and three patients died.¹⁷ Of a total of 520 patients who were included in the 3 month follow-up, 40 patients had no complete values for the 6MWT at baseline and/or the 3 month follow-up. For this secondary analysis, we used data of the 480 patients in the HF-Wii study who had completed a 6MWT both at baseline and at the 3 month follow-up. The mean age of the patients included in the present study was 67 years, and approximately 30% were female, 64% were classified as NYHA II (*Table 1*). There were no significant differences between the 145 patients that terminated the study prematurely or did not complete the 6MWT and the 480 patients included in the analysis concerning age, sex, and NYHA class.

Table 1 Baseline characteristics of the sample (N = 480)

| | All (N = 480) | 6MWT distance at baseline < 300 m (n = 79) | 6MWT distance at baseline ≥ 300 m (n = 401) | P value |
|--|-----------------|--|---|---------|
| 6MWT distance (m) | | | | |
| At baseline | 421.0 ± 131.3 | 195.9 ± 70.5 | 465.4 ± 87.8 | <0.001 |
| At 3 months | 436.5 ± 126.5 | 256.1 ± 93.6 | 472.0 ± 98.9 | <0.001 |
| Absolute changes in 6MWT (m) | 15.5 ± 65.9 | 60.2 ± 86.4 | 6.7 ± 57.2 | <0.001 |
| Improved, 30 m < change | 160 (33%) | 47 (59%) | 113 (28%) | <0.001 |
| Equal, -30 ≤ change ≤ 30 m | 239 (50%) | 24 (30%) | 215 (54%) | |
| Deterioration, change < -30 m | 81 (17%) | 8 (10%) | 73 (18%) | |
| Relative changes in 6MWT distance, %, median (Q1–Q3) | 3.3 (-3.5–11.7) | 25.4 (3.2–69.2) | 2.4 (-4.5–8.0) | <0.001 |
| Group, exergame | 238 (50%) | 32 (41%) | 206 (51%) | 0.078 |
| Age (years) | 66.7 ± 11.3 | 73.3 ± 9.3 | 65.4 ± 11.3 | <0.001 |
| Gender, female | 134 (28%) | 109 (27%) | 109 (27%) | 0.419 |
| Married/living together | 351 (74%) | 50 (63%) | 301 (76%) | 0.023 |
| With grandchildren | 322 (68%) | 66 (84%) | 256 (65%) | 0.001 |
| Education | | | | 0.003 |
| Low (compulsory school) | 117 (25%) | 31 (39%) | 86 (24%) | |
| Medium (upper secondary education) | 118 (45%) | 29 (37%) | 189 (47%) | |
| High (university/college) | 245 (30%) | 19 (24%) | 126 (31%) | |
| NYHA functional classification | | | | <0.001 |
| I | 45 (9.8%) | 2 (2.6%) | 43 (11%) | |
| II | 294 (64%) | 33 (43%) | 261 (68%) | |
| III | 119 (26%) | 41 (54%) | 78 (20%) | |
| Ischemic aetiology of HF | 197 (42%) | 28 (36%) | 169 (43%) | 0.225 |
| Duration of HF (months) | 20 (6–72) | 12 (2–72) | 23 (7–72) | 0.056 |
| LVEF dysfunction | | | | 0.006 |
| Normal | 96 (20%) | 24 (31%) | 72 (18%) | |
| Mild | 144 (30%) | 28 (35%) | 116 (29%) | |
| Moderate to severe | 237 (50%) | 27 (34%) | 210 (53%) | |
| NT pro-BNP, pg/mL median, (Q1–Q3) | 681 (250–1790) | 2247 (942–4127) | 620 (244–1552) | <0.001 |
| Pulse rate (beat/min) | 69.7 ± 12.1 | 73.3 ± 11.2 | 68.9 ± 12.2 | 0.001 |
| Systolic BP (mmHg) | 123.4 ± 17.8 | 122.2 ± 19.0 | 123.7 ± 17.6 | 0.502 |
| Diastolic BP (mmHg) | 72.3 ± 11.5 | 69.8 ± 9.8 | 72.8 ± 11.8 | 0.020 |
| Serum haemoglobin (g/dL) | 13.5 ± 1.7 | 12.4 ± 1.9 | 13.7 ± 1.6 | <0.001 |
| Serum creatinine (μmol/L) | 101.2 ± 36.1 | 107.3 ± 50.5 | 100.0 ± 32.5 | 0.229 |
| Body mass index (kg/m ²) | 27.9 ± 4.8 | 27.2 ± 5.7 | 28.0 ± 4.6 | 0.235 |
| Comorbidity | | | | |
| Cerebrovascular disease | 48 (10%) | 10 (13%) | 38 (9.7%) | 0.423 |
| Diabetes | 116 (25%) | 28 (35%) | 88 (22%) | 0.014 |
| COPD | 76 (16%) | 26 (33%) | 50 (13%) | <0.001 |
| Cancer | 49 (10%) | 6 (7.6%) | 43 (11%) | 0.370 |
| Medical therapy | | | | |
| ACEI and/or ARB | 418 (87%) | 48 (61%) | 370 (93%) | <0.001 |
| Beta-blocker | 423 (89%) | 55 (70%) | 368 (93%) | <0.001 |
| MRA | 237 (50%) | 30 (38%) | 207 (52%) | 0.023 |
| CRT | 54 (11%) | 9 (12%) | 45 (11%) | 0.916 |
| ICD | 118 (25%) | 13 (17%) | 105 (27%) | 0.079 |
| Current smoker | 37 (7.1%) | 7 (8.9%) | 27 (6.8%) | 0.512 |
| Heart failure symptoms | | | | |
| Short of breath score | 4.5 ± 2.6 | 3.9 ± 3.1 | 4.6 ± 2.5 | 0.070 |
| Fatigue score | 4.6 ± 2.6 | 5.0 ± 2.8 | 4.6 ± 2.5 | 0.201 |
| Cognitive impairment | | | | |
| MoCA score | 24.7 ± 3.4 | 21.9 ± 4.2 | 25.3 ± 3.0 | <0.001 |
| No or light | 163 (34%) | 10 (13%) | 153 (39%) | <0.001 |
| Mild | 292 (62%) | 54 (68%) | 238 (60%) | |
| Moderate | 19 (4.0%) | 15 (19%) | 4 (1.0%) | |
| Depression | 102 (22%) | 30 (39%) | 72 (18%) | <0.001 |
| HADS depression score | 4.9 ± 3.6 | 7.0 ± 4.0 | 4.5 ± 3.4 | <0.001 |
| Anxiety | 139 (29%) | 36 (47%) | 103 (26%) | <0.001 |
| HADS anxiety score | 5.4 ± 4.0 | 6.9 ± 4.6 | 5.1 ± 3.8 | <0.001 |
| Motivation score | 2.3 ± 0.9 | 2.7 ± 0.9 | 2.2 ± 0.8 | <0.001 |
| Self-efficacy score | 5.1 ± 2.0 | 4.3 ± 1.9 | 5.3 ± 1.9 | 0.001 |
| Physical activity | 3.8 ± 1.2 | 3.7 ± 1.5 | 3.8 ± 1.2 | 0.369 |
| 1, No activity | 36 (7.6%) | 12 (15%) | 24 (6.1%) | 0.031 |
| 2, <30 min/week | 37 (7.8%) | 6 (7.6%) | 31 (7.8%) | |
| 3, 30–60 min/week | 84 (18%) | 10 (13%) | 74 (19%) | |
| 4, <1 h ≤ 3 h/week | 141 (30%) | 18 (23%) | 123 (31%) | |
| 5, >3 h/week | 178 (37%) | 33 (42%) | 145 (37%) | |

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; HADS, hospital anxiety and depression scale; ICD, implantable cardioverter defibrillator; MoCA, Montreal Cognitive Assessment; MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart Association.

Eighty-four per cent of the patients ($n = 401$) had a baseline 6MWT distance of ≥ 300 m, and 36 patients walked more than 600 m during the baseline test. In total, 16% of the patients ($n = 79$) walked less than 300 m, with seven patients having a baseline 6MWT distance of fewer than 100 m. Compared with patients with a baseline 6MWT distance of ≥ 300 m, patients with a 6MWT distance of < 300 m were significantly older (65 vs. 73 years), had higher NYHA class (NYHA \geq III, 20% vs. 54%), had more mild or moderate cognitive impairment (61% vs. 87%), and had more comorbidities such as diabetes (22% vs. 35%), chronic obstructive pulmonary disease (13% vs. 33%), and depression (18% vs. 39%) (Table 1).

Factors related to lack of improvement in submaximal exercise capacity across the total group

The mean change of the 6MWT between baseline and at 3 months in the entire group was an increase of 15.5 ± 65.9 m. In total, 33% of the patients ($n = 160$) improved more than 30 m at 3 months, 50% ($n = 239$) had no clinically significant change (≤ 30 m), and 17% ($n = 81$) deteriorated in distance walked on the 6MWT by more than 30 m. Table 2 shows the results of univariate analysis after correcting for baseline distance of 6MWT. A multivariate analysis adjusted for baseline 6MWT and group assignment showed that lower levels of self-reported physical activity [odds ratio (OR) = 0.81, 95% confidence interval (CI) = 0.65–0.997] and lower cognitive function (OR = 0.87, 95%CI = 0.80–0.94) were independent predictors of lack of improvement in submaximal exercise capacity at 3 months in all study patients. Not being in the exergame group was likely to be associated with a lack of improvement (OR = 0.63, 95%CI = 0.37–1.09, $P = 0.097$).

Factors related to lack of improvement in submaximal exercise capacity according to baseline 6MWT distance (< 300 and ≥ 300 m)

Among the 79 patients with a 6MWT distance of < 300 m at baseline, 59% of the patients ($n = 47$) improved the distance walked at 3 months, 41% ($n = 32$) did not improve their distance. The mean change in distance of 6MWT between baseline and 3 months was an increase of 60.2 ± 86.4 m. Results of univariate analysis after the baseline correction of 6MWT are shown in Table 2. In the multivariate analysis, independent predictors for the lack of improvement for 6MWT were NYHA III/IV (OR = 4.68, 95%CI = 1.08–20.35), higher levels of serum creatinine (OR = 1.02, 95%CI = 1.003–1.03), lower cognitive function (OR = 0.86, 95%CI = 0.75–0.99), and fewer anxiety symptoms (OR = 0.84, 95%CI = 0.72–0.98).

Among the 401 patients with a higher baseline 6MWT distance of ≥ 300 m, the mean changes in the distance of 6MWT increased by 6.7 ± 57.2 m. Eighteen per cent of the patients ($n = 73$) deteriorated more than 30 m in 6MWT distance at 3 months, 28% ($n = 113$) improved, and 54% ($n = 215$) stayed the same. Lower levels of physical activity (OR = 0.77, 95%CI = 0.60–0.97) and lower cognitive function (OR = 0.87, 95%CI = 0.79–0.96) were significantly associated with lack of improvement for 6MWT. Not being in the exergame group was likely to be associated with a lack of improvement only in the patients with a baseline 6MWT distance of ≥ 300 m Tables 3 and 4.

Discussion

Our findings showed that lower self-reported physical activity and cognitive impairment were predictors of lack of improvement in submaximal exercise capacity in patients. However, when we analysed data from patients who scored < 300 and ≥ 300 m on the 6MWT, we identified different predictors of lack of improvement in submaximal exercise capacity. Lack of improvement was specifically associated with higher NYHA class, higher creatinine, worse cognitive impairment, and lower anxiety in patients who walked < 300 m at the 6MWT, and lower self-reported physical activity and worse cognitive impairment in those who walked ≥ 300 m in the 6MWT. To our knowledge, no prior studies have analysed predictors of lack of improvement in exercise capacity separately.

Two important messages can be derived from this study in which we analysed the change of submaximal exercise capacity in 480 patients with HF enrolled in an activity trial. The first main message is to consider the complex nature of change in exercise capacity in a sample of patients with considerable comorbidity and different exercise capacity levels before an intervention, who have challenges with cognition and psychosocial issues. Second, it is vital to reflect on the optimal use of 6MWT as an endpoint of activity trials in HF patients.

In this study, in patients who scored < 300 m at the 6MWT at baseline, lack of improvement in exercise capacity was predicted by higher NYHA class, higher creatinine, worse cognitive impairment, and lower anxiety. Several of these factors are also considered in the definition of frailty in patients with HF, in which four domains are recognized: clinical (e.g. comorbidities), psycho-cognitive (e.g. cognitive impairment), functional (e.g. low mobility), and social (poor/no social support).²⁶ The prevalence of frailty is around 40% in patients with HF.²⁷ Several factors included in the above four domains can be addressed with interventions to improve outcomes, and exercise capacity is one variable. Trials focused on improving exercise capacity in frail HF patients are scarce,

Table 2 Factors related to lack of improvement in submaximal exercise capacity in all patients (*N* = 480)

| | Univariate analysis after baseline correction of 6MWT | | | | Multivariate analysis | | | |
|---------------------------------|---|-------|-------|----------------|-----------------------|-------|-------|----------------|
| | OR | 95%CI | | <i>P</i> value | OR | 95%CI | | <i>P</i> value |
| | | Lower | Upper | | | Lower | Upper | |
| Baseline 6MWT distance | 1.002 | 1.000 | 1.004 | 0.045 | 1.01 | 1.002 | 1.01 | <0.001 |
| Randomization, Wii | 0.73 | 0.44 | 1.004 | 0.218 | 0.63 | 0.37 | 1.09 | 0.097 |
| Age | 1.02 | 0.99 | 1.04 | 0.211 | | | | |
| Gender, female | 1.14 | 0.66 | 1.97 | 1.648 | | | | |
| Married/living together | 1.03 | 0.58 | 1.83 | 0.913 | | | | |
| Grandchildren | 0.72 | 0.41 | 1.25 | 0.244 | | | | |
| Education, ≥University | 1.09 | 0.64 | 1.86 | 0.752 | | | | |
| NYHA class, III/IV | 1.89 | 1.00 | 3.56 | 0.050 | | | | |
| Ischemic aetiology | 1.48 | 0.88 | 2.52 | 0.142 | | | | |
| Duration of HF, ≥2 years | 0.98 | 0.58 | 1.66 | 0.949 | | | | |
| LVEF dysfunction | 0.97 | 0.69 | 1.34 | 0.835 | | | | |
| Pulse rate (beat/min) | 1.02 | 1.002 | 1.04 | 0.034 | | | | |
| Systolic BP (mmHg) | 1.002 | 0.99 | 1.02 | 0.770 | | | | |
| Diastolic BP (mmHg) | 1.003 | 0.98 | 1.03 | 0.769 | | | | |
| Body mass index | 0.98 | 0.93 | 1.04 | 0.576 | | | | |
| Comorbidity, yes | | | | | | | | |
| Stroke | 0.90 | 0.39 | 2.11 | 0.813 | | | | |
| Diabetes | 1.11 | 0.62 | 1.98 | 0.734 | | | | |
| Renal disease | 1.23 | 0.48 | 3.14 | 0.664 | | | | |
| COPD | 1.33 | 0.67 | 2.66 | 0.412 | | | | |
| Cancer | 0.89 | 0.38 | 2.08 | 0.791 | | | | |
| Therapy, yes | | | | | | | | |
| ACEI/ARB | 0.83 | 0.37 | 1.88 | 0.662 | | | | |
| Beta-blocker | 0.63 | 0.29 | 1.36 | 0.239 | | | | |
| MRA | 1.19 | 0.72 | 1.95 | 0.505 | | | | |
| CRT | 1.21 | 0.58 | 2.53 | 0.619 | | | | |
| ICD | 0.63 | 0.34 | 1.17 | 0.145 | | | | |
| Serum haemoglobin (g/dL) | 0.96 | 0.81 | 1.12 | 0.586 | | | | |
| Serum creatinine, μmol/L | 1.00 | 0.99 | 1.01 | 0.945 | | | | |
| Current smoker | 1.30 | 0.51 | 3.30 | 0.586 | | | | |
| Heart failure symptoms | | | | | | | | |
| Short of breath score | 1.00 | 0.91 | 1.10 | 0.976 | | | | |
| Fatigue score | 0.99 | 0.90 | 1.10 | 0.896 | | | | |
| Physical activity self-reported | 0.83 | 0.68 | 1.02 | 0.073 | 0.81 | 0.65 | 0.997 | 0.047 |
| MoCA cognitive score | 0.88 | 0.81 | 0.95 | 0.001 | 0.87 | 0.80 | 0.94 | 0.001 |
| HADS depression score | 0.99 | 0.92 | 1.07 | 0.824 | | | | |
| HADS anxiety score | 1.03 | 0.96 | 1.09 | 0.433 | | | | |
| Motivation score | 1.33 | 0.97 | 1.82 | 0.076 | | | | |
| Self-efficacy score | 1.11 | 0.97 | 1.28 | 0.133 | | | | |

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CCI, Charlson comorbidity index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; HADS, hospital anxiety and depression scale; ICD, implantable cardioverter defibrillator; MoCA, Montreal Cognitive Assessment; MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart Association; OR, odds ratio.

Dependent variable: change of 6MWT distance between baseline and 3 months < −30 m.

but a recent study²⁸ demonstrated that exercise capacity in frail HF patients could achieve a greater improvement with high-intensity training.

The second lesson from this study is that using the 6MWT as an endpoint is valuable but should be considered with its limitations. Although the 6MWT has been used in previous HF studies to measure exercise capacity²⁸ and can measure changes over time, ceiling effects can occur. In patients with preserved exercise capacity, the ceiling effect may be a limitation to consider the lack of improvement. Our study had 36 patients who walked more than 600 m in the 6MWT during the baseline test, and probably, this group of patients is not expected to increase a score that has been reported in

healthy adults in prior studies (range from 400 to 700 m).²⁹ In a study of patients with pulmonary arterial hypertension, a ceiling effect was found, and it was difficult to determine the changes in walking distance in patients with a baseline 6MWT higher than 450 m.¹⁶ The 6MWT is often used to substitute the cardiorespiratory assessment of peak oxygen consumption in a maximal symptom-limited exercise and not specifically to measure physical activity. The 6MWT might perform better in patients with severe and symptomatic HF, whose 6MWT is most severely limited and an improvement could be clinically meaningful.¹² However, at the same time, we found that 40% of patients who had a relatively low 6MWT at baseline, and in whom one expects an increase

Table 3 Predictors for lack of improvement and decline after baseline correction according to 6 min walk distance at baseline: univariate analysis

| | 6MWT < 300 m (n = 81) | | | | 6MWT ≥ 300 m (n = 401) | | | |
|---------------------------|-----------------------|-----------------------|-------|---------|------------------------|----------------------|-------|---------|
| | OR | 6MWT changes of ≤30 m | | P value | OR | 6MWT change of ≤30 m | | P value |
| | | Lower | Upper | | | Lower | Upper | |
| Lack of improvement | | 95%CI | | | | 95%CI | | |
| Baseline 6MWT distance | 1.01 | 0.999 | 1.01 | 0.117 | 1.002 | 0.999 | 1.005 | 0.236 |
| Randomization, Wii | 0.97 | 0.37 | 2.40 | 0.942 | 0.71 | 0.42 | 1.22 | 0.223 |
| Age | 1.08 | 1.01 | 1.14 | 0.016 | 1.01 | 0.98 | 1.04 | 0.490 |
| Gender, female | 1.87 | 0.66 | 5.31 | 0.242 | 1.19 | 0.67 | 2.14 | 0.551 |
| Married/living together | 0.72 | 0.27 | 1.91 | 0.505 | 0.96 | 0.52 | 1.76 | 0.894 |
| Grandchildren | 0.64 | 0.17 | 2.34 | 0.497 | 0.79 | 0.44 | 1.40 | 0.412 |
| Education, ≥University | 0.54 | 0.17 | 1.76 | 0.307 | 1.16 | 0.67 | 2.02 | 0.600 |
| NYHA class, III/IV | 3.68 | 1.16 | 11.72 | 0.027 | 1.68 | 0.84 | 3.36 | 0.146 |
| Ischemic aetiology | 2.02 | 0.74 | 5.52 | 0.168 | 1.58 | 0.90 | 2.78 | 0.110 |
| Duration of HF, ≥2 years | 2.03 | 0.74 | 5.57 | 0.169 | 0.95 | 0.54 | 1.68 | 0.868 |
| LVEF dysfunction | 0.88 | 0.49 | 1.59 | 0.674 | 0.94 | 0.66 | 1.34 | 0.730 |
| Pulse rate (beat/min) | 0.99 | 0.95 | 1.03 | 0.525 | 1.02 | 0.999 | 1.04 | 0.061 |
| Systolic BP (mmHg) | 1.001 | 0.98 | 1.03 | 0.930 | 1.002 | 0.99 | 1.02 | 0.776 |
| Diastolic BP (mmHg) | 1.02 | 0.97 | 1.07 | 0.420 | 1.01 | 0.98 | 1.03 | 0.685 |
| Body mass index | 1.05 | 0.97 | 1.15 | 0.223 | 0.97 | 0.92 | 1.03 | 0.370 |
| Comorbidity | | | | | | | | |
| Stroke | 2.30 | 0.58 | 9.19 | 0.238 | 0.90 | 0.36 | 2.25 | 0.817 |
| Diabetes | 1.16 | 0.45 | 3.04 | 0.758 | 1.10 | 0.59 | 2.07 | 0.758 |
| Renal disease | 1.39 | 0.44 | 4.39 | 0.578 | 1.58 | 0.55 | 4.49 | 0.395 |
| COPD | 1.73 | 0.63 | 4.80 | 0.289 | 1.14 | 0.52 | 2.52 | 0.739 |
| Cancer | 0.63 | 0.10 | 3.79 | 0.613 | 0.83 | 0.33 | 2.07 | 0.690 |
| Medical therapy | | | | | | | | |
| ACE/ARB | 1.14 | 0.44 | 2.96 | 0.782 | 0.72 | 0.27 | 1.88 | 0.499 |
| Beta-blocker | 0.63 | 0.23 | 1.73 | 0.370 | 0.71 | 0.28 | 1.86 | 0.490 |
| MRA | 1.08 | 0.42 | 2.81 | 0.874 | 1.13 | 0.66 | 1.92 | 0.661 |
| CRT | 2.06 | 0.50 | 8.51 | 0.319 | 1.03 | 0.45 | 2.33 | 0.947 |
| ICD | 1.36 | 0.40 | 4.57 | 0.625 | 0.55 | 0.28 | 1.08 | 0.080 |
| Serum haemoglobin (g/dL) | 0.98 | 0.76 | 1.25 | 0.840 | 1.00 | 0.84 | 1.19 | 0.975 |
| Serum creatinine (μmol/L) | 1.01 | 1.003 | 1.03 | 0.009 | 0.999 | 0.99 | 1.01 | 0.750 |
| Current smoker | — | | | | 1.57 | 0.60 | 4.14 | 0.359 |
| Heart failure symptoms | | | | | | | | |
| Short of breath score | 1.03 | 0.88 | 1.19 | 0.745 | 1.002 | 0.90 | 1.12 | 0.974 |
| Fatigue score | 1.02 | 0.85 | 1.21 | 0.874 | 0.99 | 0.89 | 1.11 | 0.902 |
| Physical activity | 0.94 | 0.68 | 1.30 | 0.703 | 0.79 | 0.63 | 0.98 | 0.035 |
| MoCA cognitive score | 0.87 | 0.77 | 0.99 | 0.030 | 0.87 | 0.80 | 0.95 | 0.002 |
| HADS depression score | 0.98 | 0.87 | 1.10 | 0.705 | 1.002 | 0.93 | 1.08 | 0.954 |
| HADS anxiety score | 0.91 | 0.81 | 1.01 | 0.092 | 1.05 | 0.98 | 1.13 | 0.137 |
| Motivation score | 1.42 | 0.84 | 2.41 | 0.191 | 1.32 | 0.94 | 1.85 | 0.111 |
| Self-efficacy score | 1.08 | 0.83 | 1.42 | 0.556 | 1.03 | 0.89 | 1.20 | 0.685 |
| EHFScBS self-care score | 0.99 | 0.97 | 1.01 | 0.393 | 0.99 | 0.98 | 1.01 | 0.178 |

6MWT, distance in 6 min walk test; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CCI, Charlson comorbidity index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; HADS, hospital anxiety and depression scale; ICD, implantable cardioverter defibrillator; MoCA, Montreal Cognitive Assessment; MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart Association; OR, odds ratio.

Higher MoCA scores indicate better cognitive function. LVEF dysfunction (1 = normal, 2 = mild, 3 = moderate to severe)

after an activity intervention, did not improve submaximal exercise capacity. In this group in which all patients had a relatively low baseline level, even their baseline 6MWT was independently associated with lack of improvement. This strong association with the baseline might indicate that these patients might be so symptomatic or suffer from comorbidity that a rather low intensity intervention might not be enough for them to improve their submaximal exercise capacity significantly.

Finally, we found that not being in the exergame group was likely to be associated with a lack of improvement only

in the patients with a baseline 6MWT distance of ≥300 m. In the main study, we did not find a significant effect of exergaming in the total sample,¹⁷ but the current results confirm that future efforts should be made to tailor interventions to patients who are most susceptible to change. Exergaming might be suitable for some, while other patients might benefit from more conventional exercise programmes, such as walking, training in a gym, and hydrotherapy.

The present study has clinical relevance by studying an activity intervention in an international group of patients with HF and provides insight into factors related to change in

Table 4 Independent predictors for lack of improvement according to the 6 min walk distance at baseline in a multivariate logistic regression analysis

| Lack of improvement | 6MWT < 300 m (n = 72) | | | | 6MWT ≥ 300 m (n = 345) | | | |
|---------------------------|--|-------|-------|---------|--------------------------------------|-------|-------|---------|
| | Equal or deterioration 6MWT changes of <30 m | | | | Deterioration 6MWT change of < -30 m | | | |
| | OR | 95%CI | | P value | OR | 95%CI | | P value |
| | | Lower | Upper | | | Lower | Upper | |
| Baseline 6MWT distance | 1.01 | 1.000 | 1.02 | 0.043 | 1.01 | 1.002 | 1.01 | 0.004 |
| Randomization, Wii | 1.05 | 0.31 | 3.56 | 0.941 | 0.61 | 0.34 | 1.09 | 0.092 |
| NYHA class, III/IV | 4.68 | 1.08 | 20.35 | 0.040 | — | — | — | — |
| Serum creatinine (μmol/L) | 1.02 | 1.003 | 1.03 | 0.014 | — | — | — | — |
| Physical activity | — | — | — | — | 0.77 | 0.60 | 0.97 | 0.029 |
| MoCA cognitive score | 0.86 | 0.75 | 0.99 | 0.048 | 0.87 | 0.79 | 0.96 | 0.003 |
| HADS anxiety score | 0.84 | 0.72 | 0.98 | 0.031 | — | — | — | — |

6MWT, distance in 6 min walk test; CI, confidence interval; HADS, hospital anxiety and depression scale; MoCA, Montreal Cognitive Assessment; MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart Association; OR, odds ratio.

Physical activity (1 = no activity, 2 = less than 30 min/week, 3 = 30–60 min/week, 4 = more than 1 h up till 3 h/week, 5 = more than 3 h a week). Higher MoCA scores indicate better cognitive function. Higher HADS anxiety scores indicate having more anxiety symptoms.

submaximal exercise capacity of patients who received an exercise intervention. The threshold of 300 m of the 6MWT can be used to tailor interventions. According to this study, as well as others,³⁰ the patients who walked <300 m at the 6MWT are more likely to be frail. They may need a more comprehensive intervention to influence exercise capacity, including an individually tailored exercise programme with aerobic exercise (if tolerated) and strength exercises. Other aspects such as adequate treatment of comorbidities and depression and social support might be included. This study is limited by being a secondary analysis. Furthermore, a total of 6.6% of patients did not have complete values of the 6MWT at baseline and/or 3 month follow-up, mostly due to physical impairments. Patients who could not perform the 6MWT at baseline probably had a 6MWT lower than 300 m, and patients that could not perform the 6MWT at follow-up had most likely a decline in 6MWT.

Conclusions and clinical implications

Lack of improvement in submaximal exercise capacity in HF patients was associated with lower self-reported physical activity and cognitive impairment. These findings are important because they may help health care professionals to identify non-responding patients with HF suitable for participation in interventions aimed at improving physical activity (advice and exergame in our HF-Wii study). Patients with a worse prognosis (score <300 m at the 6MWT), who may be defined as frail, gained less in exercise capacity. These patients may need a more comprehensive approach to have an effect on exercise capacity, including an individually tailored exercise programme, with aerobic exercise (if tolerated) and strength exercises, for example, an individually adapted and coached exercise programme.

Acknowledgements

Authors acknowledge the following: A. Hammarskiöld, L. Nestor, C. Norrman, R.M. Petterson, M. Viklander, A. Waldemar, and M. Wärfman from Norrköping. E. Lundberg, M. Sahlin, and H. Sköldbäck from Jönköping. A. Gylling, L. Hjelmfors, M. Huss, M. Jonsson, P. Wodlin. Stockholm: E. Hägglund, and U. Lenmark from Linköping. E. Säfström from Nyköping. J. Boyne, H.P. Brunner-La Rocca, G. Cleuren, M. Spanjers, and A. van de Voorde from the Netherlands. R. Corsi and G.A. Ortali from Italy. B. Ben Avraham, S. Donanhirsh, Y. Navon, and V. Yaari from Israel. A. Hagenow and A. Kuntzsch from Germany. J. Ardo, J. Nguyen, and M. Cacciata from the United States.

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

This work was supported by the Swedish National Science Council (K2013-69X-22302-01-3, 2016-01390), the Swedish National Science Council/the Swedish Research Council for Health, Working Life and Welfare, VR-FORTE (2014-4100), the Swedish Heart and Lung Association (E085/12), the Swedish Heart and Lung Foundation (20130340, 20160439), the Vårdal Foundation (2014-0018), and the Medical Research Council of Southeast Sweden (FORSS 474681).

References

- Cacciatore F, Amarelli C, Ferrara N, Della Valle E, Curcio F, Liguori I, Bosco Q, Maiello C, Napoli C, Bonaduce D, Abete P. Protective effect of physical activity on mortality in older adults with advanced chronic heart failure: a prospective observational study. *Eur J Prev Cardiol* 2019; **26**: 481–488.
- Piepoli MF, Binno S, Corra U, Seferovic P, Conraads V, Jaarsma T, Schmid JP, Filippatos G, Ponikowski PP, Committee on Exercise Physiology & Training of the Heart Failure Association of the ESC. ExtraHF survey: the first European survey on implementation of exercise training in heart failure patients. *Eur J Heart Fail* 2015; **17**: 631–638.
- Piepoli MF, Conraads V, Corra U, Dickstein K, Francis DP, Jaarsma T, McMurray J, Pieske B, Piotrowicz E, Schmid JP, Anker SD, Solal AC, Filippatos GS, Hoes AW, Gielen S, Giannuzzi P, Ponikowski PP. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. *Eur J Heart Fail* 2011; **13**: 347–357.
- Jaarsma T, Hill L, Bayes-Genis A, La Rocca HB, Castiello T, Čelutkienė J, Marques-Sule E, Plymen CM, Piper SE, Riegel B, Rutten FH, Ben Gal T, Bauersachs J, Coats AJS, Chioncel O, Lopatin Y, Lund LH, Lainscak M, Moura B, Mullens W, Piepoli MF, Rosano G, Seferovic P, Strömberg A. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2020; **22**: 1939–1940.
- Duncan K, Pozehl B, Hertzog M, Norman JF. Psychological responses and adherence to exercise in heart failure. *Rehabil Nurs Off J Assoc Rehabil Nurs* 2014; **39**: 130–139.
- Ingle L, Shelton RJ, Rigby AS, Nabb S, Clark AL, Cleland JG. The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure. *Eur Heart J* 2005; **26**: 1742–1751.
- Stewart RA, Szalewska D, She L, Lee KL, Drazner MH, Lubiszewska B, Kosevic D, Ruengsakulrach P, Nicolau JC, Coutu B, Choudhary SK, Mark DB, Cleland JG, Piña IL, Velazquez EJ, Rynkiewicz A, White H. Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure). *JACC Heart Fail* 2014; **2**: 335–343.
- Ingle L, Cleland JG, Clark AL. The relation between repeated 6-minute walk test performance and outcome in patients with chronic heart failure. *Ann Phys Rehabil Med* 2014; **57**: 244–253.
- Ferreira JP, Duarte K, Graves TL, Zile MR, Abraham WT, Weaver FA, Lindenfeld JA, Zannad F. Natriuretic peptides, 6-min walk test, and quality-of-life questionnaires as clinically meaningful endpoints in HF trials. *J Am Coll Cardiol* 2016; **68**: 2690–2707.
- Grundtvig M, Eriksen-Volnes T, Ørn S, Slind EK, Gullestad L. 6 min walk test is a strong independent predictor of death in outpatients with heart failure. *ESC Heart Fail* 2020; **7**: 2904–2911.
- Rostagno C. Six-minute walk test: independent prognostic marker? *Heart* 2010; **96**: 97–98.
- Ferreira JP, Metra M, Anker SD, Dickstein K, Lang CC, Ng L, Samani NJ, Cleland JG, van Veldhuisen DJ, Voors AA, Zannad F. Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSAT-CHF study. *Eur J Heart Fail* 2019; **21**: 218–226.
- Shoemaker MJ, Curtis AB, Vangsnes E, Dickinson MG. Clinically meaningful change estimates for the six-minute walk test and daily activity in individuals with chronic heart failure. *Cardiopulm Phys Ther J* 2013; **24**: 21–29.
- Abraham WT, Young JB, León AR, Adler S, Bank AJ, Hall SA, Lieberman R, Liem LB, O'Connell JB, Schroeder JS, Wheelan KR, Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. *Circulation* 2004; **110**: 2864–2868.
- Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM, Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004; **350**: 2140–2150.
- Frost AE, Langleben D, Oudiz R, Hill N, Horn E, McLaughlin V, Robbins IM, Shapiro S, Tapson VF, Zwicke D, DeMarco T, Schilz R, Rubenfire M, Barst RJ. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. *Vascul Pharmacol* 2005; **43**: 36–39.
- Jaarsma T, Klompstra L, Ben Gal T, Ben Avraham B, Boyne J, Bäck M, Chialà O, Dickstein K, Evangelista L, Hagenow A, Hoes AW, Hägglund E, Piepoli MF, Vellone E, Zuithoff NPA, Mårtensson J, Strömberg A. Effects of exergaming on exercise capacity in patients with heart failure: results of an international multicentre randomized controlled trial. *Eur J Heart Fail* 2020; **22**: 1939–1940.
- Jaarsma T, Klompstra L, Ben Gal T, Boyne J, Vellone E, Bäck M, Dickstein K, Fridlund B, Hoes A, Piepoli MF, Chialà O, Mårtensson J, Strömberg A. Increasing exercise capacity and quality of life of patients with heart failure through Wii gaming: the rationale, design and methodology of the HF-Wii study; a multicentre randomized controlled trial. *Eur J Heart Fail* 2015; **17**: 743–748.
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002; **166**: 111–117.
- Julayanont P, Phillips N, Chertkow H, Nasreddine ZS. *Montreal Cognitive Assessment (MoCA): Concept and Clinical Review*. London: Springer; 2013.
- Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; **53**: 695–699.
- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983; **67**: 361–370.
- Stenstrom CH, Boestad C, Carlsson M, Edstrom M, Reuterhall A. Why exercise?: a preliminary investigation of an exercise motivation index among individuals with rheumatic conditions and healthy individuals. *Physiother Res Int J Res Clin Phys Ther* 1997; **2**: 7–16.
- Bauman AE, Sallis JF, Dzawaltowski DA, Owen N. Toward a better understanding of the influences on physical activity: the role of determinants, correlates, causal variables, mediators, moderators, and confounders. *Am J Prev Med* 2002; **23**: 5–14.
- Liljeroos M, Agren S, Jaarsma T, Arestedt K, Stromberg A. Long term follow-up after a randomized integrated educational and psychosocial intervention in patient-partner dyads affected by heart failure. *PLoS One* 2015; **10**: e0138058.
- Vitale C, Jankowska E, Hill L, Piepoli M, Doehner W, Anker SD, Lainscak M, Jaarsma T, Ponikowski P, Rosano GMC, Seferovic P, Coats AJ. Heart failure Association/European Society of Cardiology position paper on frailty in patients with heart failure. *Eur J Heart Fail* 2019; **21**: 1299–1305.
- Marengoni A, Zucchelli A, Vetrano DL, Aloisi G, Brandi V, Ciutan M, Panait CL, Bernabei R, onder G, Palmer K. Heart failure, frailty, and pre-frailty: a systematic review and meta-analysis of

- observational studies. *Int J Cardiol* 2020; **316**: 161–171.
28. Papathanasiou JV. Are the group-based interventions improving the functional exercise capacity and quality of life of frail subjects with chronic heart failure? *J Frailty Sarcopenia Falls* 2020; **5**: 102–108.
29. Enright PL. The six-minute walk test. *Respir Care* 2003; **48**: 783–785.
30. Pandey A, Kitzman D, Whellan DJ, Duncan PW, Mentz RJ, Pastva AM, Nelson MB, Upadhyya B, Chen H, Reeves GR. Frailty among older decompensated heart failure patients: prevalence, association with patient-centered outcomes, and efficient detection methods. *JACC Heart Fail* 2019; **7**: 1079–1088.